ZYBERNO
Stock Report
Updated Sep 1, 2026

Valion Bio, Inc. (VBIO)

Healthcare • NASDAQ

$3.07

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
Valion Bio, Inc. (VBIO) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-199.0%)
Debt-to-Equity (Solvency Risk):CRITICAL (4.72x)
Operating Margin (Operational Efficiency):CRITICAL (-3,426.6%)
Return on Capital (Capital Efficiency):CRITICAL (-124.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Valion Bio, Inc. (VBIO) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.07
Market Cap:$10.38M

Valuation Multiples (3)

P/B Ratio:2.44x
P/S Ratio:21.53x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$19.41M

Price Action & Momentum (3)

Momentum Percentile:1 / 100
% of 52-Week High:79.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-69.1%
Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.3%

Margin Analysis (3)

Operating Margin Ttm:-3,426.6%
Net Margin Ttm:-3,890.0%
Ebitda Margin:-3,350.4%

TTM Performance (3)

Gross Margin Ttm:-17.2%
Operating Margin Ttm:-3,426.6%
Net Margin Ttm:-3,890.0%

Yield Metrics (2)

Earnings Yield:-$12.10K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:21.4%
Latest Earnings Filed:2025-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-32.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.11x
Quick Ratio:0.86x
Cash Ratio:0.69x

Leverage Analysis (3)

Debt To Equity Ttm:4.72x
Debt-to-Equity Ratio:4.72x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-3.33x
Times Interest Earned:-3.33

Capital Structure (4)

Working Capital:336,000.00
Cash And Cash Equivalents:2,108,000.00
Long Term Debt:$9.49M
Net Debt:$9.03M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $482.00K
Linear Growth: -32.9%
📊 Click to view full VBIO Revenue analysis & methodology →
Cost Of Revenue Ttm:$762.00K

Profitability Breakdown (2)

Gross profit TTM: -$83.00K
Linear Growth: -6.9%
📊 Click to view full VBIO Gross Profit analysis & methodology →
-$16.52M

Bottom Line Performance (3)

-$18.75M
Income Before Tax:$8.90M
Ebitda Ttm:-16,149,000.00

Operating Expenses (5)

Operating Expenses:16,412,000.00
R And D Expense:6,699,000.00
Sga Expense:10,318,000.00
Income Tax Expense:$0.00
Interest Expense:1,346,000.00

Expense Ratios (3)

R And D To Revenue Percentage:4,588.4%
Sga To Revenue Percentage:7,067.1%
Ebitda Margin:-3,350.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$32.47M
Current Assets:$3.38M
Ppe Net:12,343,000.00
Goodwill:3,457,000.00
Intangible Assets:$2.24M

Liability Structure (4)

Total Liabilities:28,227,000.00
Current Liabilities:3,046,000.00
Long Term Debt:$9.49M
Short Term Debt:$1.65M

Equity & Capital (3)

Equity:$4.25M
Retained Earnings:-$66.51M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:19,000.00
Inventory:750,000.00
Accounts Payable:639,000.00

Special Items (2)

Contract Liabilities:3,000.00
Stock Based Compensation:133,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$11.12M-$7.04M

Investment Activities (1)

Investing Cash Flow:-$7.00K

Financing Activities (3)

Financing Cash Flow:-$44.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:8,507,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:367,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-7.53
-$23.06
Earnings Per Share Ttm:-$5.55

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.14
Operating Cash Flow Per Share:-$1.69

Book Value & Capital (2)

Book Value Per Share:$1.26
Cash Per Share:0.62

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:1.43x

Receivables Management (2)

Receivables Turnover Ttm:25.37x
Days Sales Outstanding Ttm:14.39

Inventory Management (2)

Inventory Turnover Ttm:1.02x
Days Inventory Outstanding Ttm:359.25

Payables & Cash Cycle (2)

Days Payable Outstanding:306.08
Cash Conversion Cycle:67.56
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):0.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-32.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-6.9%
Book Value Growth Rate (Linear):-2.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:VBIO
Company Name:Valion Bio, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:3.38M
Shares Outstanding Basic:3.38M
Shares Outstanding Diluted:881.29K

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 21:04:09 UTC
Data Timestamp:2026-08-22T12:24:09.524141
Scroll to Top